News >

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

Brandon Scalea
Published: Friday, Jan 11, 2019

Peter Voorhees, MD

Peter Voorhees, MD
The overall safety profile of adding daratumumab (Darzalex) to the standard triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) was consistent with data previously reported for the 3-drug regimen. These findings, along with efficacy data, suggest that this could eventually be a practice-changing option, explained Peter Voorhees, MD.

, Voorhees, an associate professor at the University of North Carolina Lineberger Comprehensive Cancer Center, discussed the clinical potential of adding daratumumab to VRd in patients with multiple myeloma.

OncLive: Please provide some background to the Griffin study.

Voorhees: We presented an updated safety and efficacy analysis from the safety run-in cohort of the Griffin trial. This is a randomized phase II trial incorporating daratumumab into the lenalidomide, bortezomib, dexamethasone backbone for newly diagnosed patients with multiple myeloma who are eligible for stem cell transplant.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x